₹1,882.10
₹-17.50 (-0.92%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹30,553 Cr
P/E
73.79
ROE
5.75%
ROCE
7.39%
About Wockhardt Ltd
Wockhardt along with its subsidiaries (the ‘Group’) is a global pharmaceutical and biotech company with presence in UK, Switzerland, Ireland, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland and Dubai. The Company has a significant presence in Europe and India.
Founded
1999
CEO
H F Khorakiwala
Employees
4,084
HQ
Mumbai, India
About Wockhardt Ltd
Wockhardt along with its subsidiaries (the ‘Group’) is a global pharmaceutical and biotech company with presence in UK, Switzerland, Ireland, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland and Dubai. The Company has a significant presence in Europe and India.
Founded:1999
CEO:H F Khorakiwala
Employees:4,084
HQ:Mumbai, India
Finished Products
1Sale of Products
₹3,825.00Cr2Sale of Services
₹232.00Cr3Export Incentives
₹148.00Cr4Other Operating Revenue
₹90.00CrRaw Materials
1Cost of Materials Consumed
₹904.00Cr2Purchase of Traded Goods
₹532.00CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹2,422
52W Low
₹1,087
Volume310.26K
Avg VolumeN/A
Beta0.94
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
73.79x
Valuation
P/B Ratio
6.18x
Valuation
EPS
₹25.48
Valuation
Dividend Yield
0.00%
Valuation
ROE
5.75%
Profitability
ROCE
7.39%
Profitability
Revenue by Segment
Contribution & growth by business line
PharmaceuticalsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
21.9%
International
78.1%
Europe49.6%
Rest of the world28.4%
India21.9%
USA/Western Europe0.0%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.45x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
6.4%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.